Slovenian recommendations for parvovirus B19 infection in pregnancy
Abstract
Parvovirus B19 (B19V) causes a mild disease called erythema infectiosum, also known as the fifh disease that affects mostly children and young adults. The virus can be transferred to the fetus during pregnancy in 31 to 51 % of the cases and can cause severe anaemia, non-immune hydrops fetalis or fetal death due to inhibition of erythropoiesis. It also affects the heart muscle, central nervous system, bones, and most likely can cause a subsequent arrest in children’s neurological development. It is estimated that 25–45 % of pregnant women are seronegative with a high risk of infection during pregnancy. A B19V infection in pregnant women is determined by detecting specific IgM and IgG antibodies, and in case of doubt, by using PCR method to detect viral DNA. Fetal infection with B19V is confirmed by detecting viral DNA in the amniotic fluid. In the case of either a suspected or confirmed fetal infection we monitor the fetus by ultrasound screening in a tertiary centre. We treat the fetus with an intrauterine transfusion at the first signs of anaemia or hydrops. To prevent fresh infections with B19V during pregnancy we should raise awareness amongst women and healthcare workers about the risks it poses for the fetus. The recommendations for management of women who are exposed to, are at risk of developing, or have developed B19V infection in pregnancy are published in this article.
Downloads
References
Cossart YE, Cant B, Field AM, Widdows D. PARVOVIRUS-LIKE PARTICLES IN HUMAN SERA. The Lancet. 1975;305(7898):72–3.
Anderson MJ, Lewis E, Kidd IM, Hall SM, Cohen BJ. An outbreak of erythema infectiosum associated with human parvovirus infection. Journal of Hygiene. 1984;93(01):85–93.
Dijkmans BA, Breedveld FC, Weiland HT. [Acute joint symptoms in a parvovirus infection]. Nederlands tijdschrift voor geneeskunde. 1986;130(38):1702-5.
Dijkmans BAC, Van Elsacker-Niele AMW, Salimans MMM, Van Albada-Kuipers GA, De Vries E, Weiland HT. Human parvovirus b19 dna in synovial fluid. Arthritis & Rheumatism. 1988;31(2):279–81.
Rao KRP. Infection with Parvovirus-like Virus and Aplastic Crisis in Chronic Hemolytic Anemia. Annals of Internal Medicine. 1983;98(6):930.
Enders M, Weidner A, Zoellner I, Searle K, Enders G. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenatal Diagnosis. 2004;24(7):513–8.
Chisaka H, Morita E, Yaegashi N, Sugamura K. Parvovirus B19 and the pathogenesis of anaemia. Reviews in Medical Virology. 2003;13(6):347–59.
Young NS, Brown KE. Parvovirus B19. New England Journal of Medicine. 2004;350(6):586–97.
Yaegashi N, Niinuma T, Chisaka H, Uehara S, Moffatt S, Tada K, et al. Parvovirus B19 infection induces apoptosis of erythroid cells in vitro and in vivo. Journal of Infection. 1999;39(1):68–76.
Weigel-Kelley KA. 5 1 integrin as a cellular coreceptor for human parvovirus B19: requirement of functional activation of 1 integrin for viral entry. Blood. 2003;102(12):3927–33.
Munakata Y. Ku80 autoantigen as a cellular coreceptor for human parvovirus B19 infection. Blood. 2005;106(10):3449–56.
de Haan T, Oepkes D, Beersma M, Walther F. Aetiology, Diagnosis and Treatment of Hydrops Foetalis. Current Pediatric Reviews. 2005;1(1):63–72.
Broliden K, Tolfvenstam T, Norbeck O. Clinical aspects of parvovirus B19 infection. Journal of Internal Medicine. 2006;260(4):285–304.
Pasquinelli G, Bonvicini F, Foroni L, Salfi N, Gallinella G. Placental endothelial cells can be productively infected by Parvovirus B19. Journal of Clinical Virology. 2009;44(1):33–8.
Kooistra K, Mesman HJ, de Waal M, Koppelman MHGM, Zaaijer HL. Epidemiology of high-level parvovirus B19 viraemia among Dutch blood donors, 2003–2009. Vox Sanguinis. 2010;100(3):261–6.
Heegaard ED, Brown KE. Human Parvovirus B19. Clinical Microbiology Reviews. 2002;15(3):485–505.
RÖHrer C, GÄRtner B, Sauerbrei A, BÖHm S, HottentrÄGer B, Raab U, et al. Seroprevalence of parvovirus B19 in the German population. Epidemiology and Infection. 2008;136(11):1564.
van Rijckevorsel GGC, Bovée LPMJ, Damen M, Sonder GJB, Schim van der Loeff MF, van den Hoek A. Increased seroprevalence of IgG-class antibodies against cytomegalovirus, parvovirus B19, and varicella-zoster virus in women working in child day care. BMC Public Health. 2012;12(1).
Valeur-Jensen AK. Risk Factors for Parvovirus B19 Infection in Pregnancy. JAMA. 1999;281(12):1099.
Dembinski J. Long term follow up of serostatus after maternofetal parvovirus B19 infection. Archives of Disease in Childhood. 2003;88(3):219–21.
de Jong EP, de Haan TR, Kroes ACM, Beersma MFC, Oepkes D, Walther FJ. Erratum to “Parvovirus B19 infection in pregnancy” [J. Clin. Virol. 36 (2006) 1–7]. Journal of Clinical Virology. 2007;38(2):188.
Norbeck O, Papadogiannakis N, Petersson K, Hirbod T, Broliden K, Tolfvenstam T. Revised Clinical Presentation of Parvovirus B19–Associated Intrauterine Fetal Death. Clinical Infectious Diseases. 2002;35(9):1032–8.
Enders M, Klingel K, Weidner A, Baisch C, Kandolf R, Schalasta G, et al. Risk of fetal hydrops and non-hydropic late intrauterine fetal death after gestational parvovirus B19 infection. Journal of Clinical Virology. 2010;49(3):163–8.
Puccetti C, Contoli M, Bonvicini F, Cervi F, Simonazzi G, Gallinella G, et al. Parvovirus B19 in pregnancy: possible consequences of vertical transmission. Prenatal Diagnosis. 2012:1–6.
Brkic S, Bogavac MA, Simin N, Hrnjakovic-Cvetkovic I, Milosevic V, Maric D. Unusual high rate of asymptomatic maternal parvovirus B19 infection associated with severe fetal outcome. The Journal of Maternal-Fetal & Neonatal Medicine. 2010;24(4):647–9.
van Kamp IL, Klumper FJCM, Bakkum RSLA, Oepkes D, Meerman RH, Scherjon SA, et al. The severity of immune fetal hydrops is predictive of fetal outcome after intrauterine treatment. American Journal of Obstetrics and Gynecology. 2001;185(3):668–73.
Bonvicini F, Puccetti C, Salfi NCM, Guerra B, Gallinella G, Rizzo N, et al. Gestational and Fetal Outcomes in B19 Maternal Infection: a Problem of Diagnosis. Journal of Clinical Microbiology. 2011;49(10):3514–8.
Weiffenbach J, Bald R, Gloning K-P, Minderer S, Gärtner BC, Weidner A, et al. Serological and Virological Analysis of Maternal and Fetal Blood Samples in Prenatal Human Parvovirus B19 Infection. The Journal of Infectious Diseases. 2012;205(5):782–8.
Cantey JB, Pritchard MA, Sanchez PJ. Bone Lesions in an Infant With Congenital Parvovirus B19 Infection. PEDIATRICS. 2013;131(5):e1659-e63.
Koch WC, Harger JH, Barnstein B, Adler SP. Serologic and virologic evidence for frequent intrauterine transmission of human parvovirus B19 with a primary maternal infection during pregnancy. The Pediatric Infectious Disease Journal. 1998;17(6):489–94.
Nyman M, Skjöldebrand-Sparre L, Broliden K. Non-hydropic intrauterine fetal death more than 5 months after primary parvovirus B19 infection. Journal of Perinatal Medicine. 2005;33(2).
Lassen J, Jensen AKV, Bager P, Pedersen CB, Panum I, Norgaard-Pedersen B, et al. Parvovirus B19 Infection in the First Trimester of Pregnancy and Risk of Fetal Loss: A Population-based Case-Control Study. American Journal of Epidemiology. 2012;176(9):803–7.
Yageashi N, Niinuma T, Chisaka H, Watanabe T, Uehara S, Okamura K, et al. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. Journal of Infection. 1998;37(1):28–35.
Simms RA, Liebling RE, Patel RR, Denbow ML, Abdel-Fattah SA, Soothill PW, et al. Management and Outcome of Pregnancies with Parvovirus B19 Infection over Seven Years in a Tertiary Fetal Medicine Unit. Fetal diagnosis and therapy. 2009;25(4):373–8.
Nunoue T, Kusuhara K, Hara T. Human fetal infection with parvovirus B19: maternal infection time in gestation, viral persistence and fetal prognosis. The Pediatric Infectious Disease Journal. 2002;21(12):1133–6.
Dijkmans AC, de Jong EP, Dijkmans BAC, Lopriore E, Vossen A, Walther FJ, et al. Parvovirus B19 in pregnancy. Current Opinion in Obstetrics and Gynecology. 2012;24(2):95–101.
De Haan TR, Van Den Akker ESA, Porcelijn L, Oepkes D, Kroes ACM, Walther FJ. Thrombocytopenia in hydropic fetuses with parvovirus B19 infection: incidence, treatment and correlation with fetal B19 viral load. BJOG: An International Journal of Obstetrics & Gynaecology. 2007;115(1):76–81.
Pistorius LR, Smal J, de Haan TR, Page-Christiaens GCML, Verboon-Maciolek M, Oepkes D, et al. Disturbance of Cerebral Neuronal Migration following Congenital Parvovirus B19 Infection. Fetal diagnosis and therapy. 2008;24(4):491–4.
Isumi H, Nunoue T, Nishida A, Takashima S. Fetal brain infection with human parvovirus B19. Pediatric Neurology. 1999;21(3):661–3.
Courtier J, Schauer GM, Parer JT, Regenstein AC, Callen PW, Glenn OA. Polymicrogyria in a fetus with human parvovirus B19 infection: a case with radiologic-pathologic correlation. Ultrasound in Obstetrics & Gynecology. 2012;40(5):604–6.
Dembinski J. Neurodevelopmental outcome after intrauterine red cell transfusion for Parvovirus B19-induced fetal hydrops. BJOG: An International Journal of Obstetrics and Gynaecology. 2002;109(11):1232–4.
Nagel HTC, de Haan TR, Vandenbussche FPHA, Oepkes D, Walther FJ. Long-Term Outcome After Fetal Transfusion for Hydrops Associated With Parvovirus B19 Infection. Obstetrics & Gynecology. 2007;109(1):42–7.
De Jong EP, Lindenburg IT, van Klink JM, Oepkes D, van Kamp IL, Walther FJ, et al. Intrauterine transfusion for parvovirus B19 infection: long-term neurodevelopmental outcome. American Journal of Obstetrics and Gynecology. 2012;206(3):204.e1-.e5.
Lassen J, Bager P, Wohlfahrt J, Bottiger B, Melbye M. Parvovirus B19 infection in pregnancy and subsequent morbidity and mortality in offspring. International Journal of Epidemiology. 2013;42(4):1070–6.
Stavec T. Posledice okužbe s parvovirusom B19 v nosečnosti [PhD Thesis]. Ljubljana: T. Stavec; 2015.
Anderson MJ, Higgins PG, Davis LR, Willman JS, Jones SE, Kidd IM, et al. Experimental Parvoviral Infection in Humans. Journal of Infectious Diseases. 1985;152(2):257–65.
Beersma MFC, Claas ECJ, Sopaheluakan T, Kroes ACM. Parvovirus B19 viral loads in relation to VP1 and VP2 antibody responses in diagnostic blood samples. Journal of Clinical Virology. 2005;34(1):71–5.
Bredl S, Plentz A, Wenzel JJ, Pfister H, Möst J, Modrow S. False-negative serology in patients with acute parvovirus B19 infection. Journal of Clinical Virology. 2011;51(2):115–20.
Enders M, Helbig S, Hunjet A, Pfister H, Reichhuber C, Motz M. Comparative evaluation of two commercial enzyme immunoassays for serodiagnosis of human parvovirus B19 infection. Journal of Virological Methods. 2007;146(1–2):409–13.
Enders M, Weidner A, Rosenthal T, Baisch C, Hedman L, Söderlund-Venermo M, et al. Improved Diagnosis of Gestational Parvovirus B19 Infection at the Time of Nonimmune Fetal Hydrops. The Journal of Infectious Diseases. 2008;197(1):58–62.
de Haan TR, Beersma MFC, Oepkes D, de Jong EP, Kroes ACM, Walther FJ. Parvovirus B19 infection in pregnancy: maternal and fetal viral load measurements related to clinical parameters. Prenatal Diagnosis. 2006;27(1):46–50.
Adams LL, Gungor S, Turan S, Kopelman JN, Harman CR, Baschat AA. When are amniotic fluid viral PCR studies indicated in prenatal diagnosis? Prenatal Diagnosis. 2012;32(1):88–93.
Delle Chiaie L, Buck G, Grab D, Terinde R. Prediction of fetal anemia with Doppler measurement of the middle cerebral artery peak systolic velocity in pregnancies complicated by maternal blood group alloimmunization or parvovirus B19 infection. Ultrasound in Obstetrics and Gynecology. 2001;18(3):232–6.
Bernstein DI, Sahly HME, Keitel WA, Wolff M, Simone G, Segawa C, et al. Safety and immunogenicity of a candidate parvovirus B19 vaccine. Vaccine. 2011;29(43):7357–63.
Jeon J, Victor M, Adler SP, Arwady A, Demmler G, Fowler K, et al. Knowledge and Awareness of Congenital Cytomegalovirus Among Women. Infectious Diseases in Obstetrics and Gynecology. 2006;2006:1–7.
Vossen A, de Vries J, van der Zeijst B. The 2008 congenital cytomegalovirus conference, 5–7 November, Centers for Disease Control and Prevention, Atlanta. Euro Surveill 2009;14:37–38. [cited 2014 May] Available from: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19136.
Society of Obstetricians and Gynaecologists of Canada (SOGC) clinical practice guideline. Parvovirus B19) Infection in Pregnancy. Guideline No. 316 (Replaces No. 119), J Obstet Gynaecol Can2014;36(12):1107–1116.
Parvovirus B19 Infection in Pregnancy. Journal of Obstetrics and Gynaecology Canada. 2002;24(9):727–34.
Practice Bulletin No. 151. Obstetrics & Gynecology. 2015;125(6):1510–25.
UK National Screening Committee: External review against programme appraisal criteria for the UK National Screening Committee (UK NSC). June 2014. [cited 2017 May 1] Available from: https://legacyscreening.phe.org.uk/parvovirus.
Geršak K, Fras Z, Rems M. Ali vemo, kakšne morajo biti dobre klinične smernice? Zdrav Vestn. 2016;85(1):6–14.
Copyright (c) 2018 Slovenian Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The Author transfers to the Publisher (Zdravniški vestnik/Slovenian Medical Journal) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Zdravniški vestnik/Slovenian Medical Journal) has the right to transfer the rights, acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
